ERBB2 and adenocarcinoma: Compared with patients with HER2 ex20ins mutations, non‐ex20ins patients were older (63 vs. 57 years, P < 0.01), had a greater proportion of smokers (41.9% vs. 21.1%, P = 0.03), and had a lower proportion of adenocarcinoma (83.9% vs. 96.1%, P = 0.02).